ICON Wins ‘Partnership Pioneers of the Year’ Award in Recognition of Global Partnership with Pfizer

  ICON Wins ‘Partnership Pioneers of the Year’ Award in Recognition of Global
  Partnership with Pfizer

Business Wire

DUBLIN -- April 24, 2013

ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries, today
announced that is has received the 2013 “Partnership Pioneers of the Year” 
award in recognition of its strategic partnership with Pfizer and PAREXEL.

Presented by the Institute for International Research and Partnerships in
Clinical Trials’ advisory board, the award recognises two or more companies
engaged in a partnership that moves beyond the traditional transactional model
to a more strategic approach that can bring innovation to the drug development
process.

ICON was selected by Pfizer in May 2011 as one of two strategic partners for
global clinical research and development. The partnership was part of Pfizer’s
comprehensive program of change in R&D to sharpen research focus, deliver
differentiated innovation, and create a more flexible cost base through
external partnerships for certain R&D services.

Commenting on the award, ICON’s CEO, Mr. Ciaran Murray, said: “I am delighted
that ICON has received this award which recognises our commitment to the
strategic collaboration with Pfizer. Using our scale, clinical experience, and
technology such as Firecrest, we are able to deliver high-quality solutions
for the Pfizer partnership. These solutions help reduce cycle times and cost
and improve the quality and productivity of drug development. Over the past
two years we have worked hard with Pfizer to transform their drug development
model and have built a solid platform that will support the continued success
and evolution of the partnership in the future.”

“Our new Alliance Partner Model is providing a solid foundation for integrated
quality clinical services,” said Dr. John Hubbard, SVP of Development
Operations for Pfizer. “ICON and PAREXEL’s clinical expertise and innovative
technology continues to set the standard for best practice, this award
recognises progress toward our goal of creating a common culture dedicated to
universally improving clinical trial implementation. We look forward to
deepening our relationship with ICON and PAREXEL, to achieve our partnership’s
full potential, and ultimately deliver medicines to patients in need more
quickly and efficiently.”

Pfizer, ICON and PAREXEL accepted the honour during an awards ceremony at the
22^nd annual Partnerships in Clinical Trials conference.

The statements made in this press release may contain forward-looking
statements that involve a number of risks and uncertainties. A description of
risks and uncertainties relating to ICON and its business can be found in
Forms 20-F for the fiscal year ended December 31^st 2012 and in the other
forms filed with the US Securities and Exchange Commission, including the F-1,
S-8 and F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.

Notes to Editors

About ICON plc

ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of programs
that support clinical development - from compound selection to Phase I-IV
clinical studies. ICON currently has approximately 10,045 employees, operating
from 79 locations in 37 countries.

Further information is available at www.iconplc.com

ICON/ICLR-G

Contact:

ICON Media Contact
Genevieve Tuck
Weber Shandwick
Tel: +44 (0)20 7067 0655
gtuck@webershandwick.com
 
Press spacebar to pause and continue. Press esc to stop.